News Archive

February 13, 2023


Lytgobi® Now Available from Onco360

February 2, 2023


ORSERDU™ Now Available from Onco360

January 30, 2023


JAYPIRCA™ (pirtobrutinib) Now Available from Onco360

December 15, 2022


Krazati (adagrasib) Now Available from Onco360

September 14, 2022


Onco360 has been added as a trusted specialty pharmacy provider for Tibsovo® (ivosidenib) tablets

June 6, 2022


ORGOVYX® (relugolix) Now Available from Onco360 for the Treatment of Adult Patients with Advanced Prostate Cancer

March 3, 2022

VONJOTM (pacritinib) Available from Onco360

Onco360 has been chosen as a trusted specialty pharmacy to dispense VONJO™ - the first FDA approved therapy that specifically addresses the needs of Adult Cytopenic Myelofibrosis.

November 18, 2021

BESREMi® Available From Onco360

BESREMi® (ropeginterferon alfa-2b-njft) Now Approved for the Treatment of Adults with Polycythemia Vera

September 17, 2021

EXKIVITYTM Available From Onco360

EXKIVITY (mobocertinib) approved and Takeda has selected Onco360® as a Specialty Pharmacy Partner

August 18, 2021

WELIREG Available From Onco360

Onco360® has been selected by Merck & Co., Inc. to be in the specialty pharmacy network for WELIREG (belzutifan) ), a hypoxia-inducible factor inhibitor indicated for the treatment of adult patients with von Hippel-Lindau (VHL) disease who require therapy for associated renal cell carcinoma (RCC), central nervous system (CNS) hemangioblastomas, or pancreatic neuroendocrine tumors (pNET), not requiring immediate surgery.

July 22, 2021

REZUROCKTM Available From Onco360

REZUROCKTM (belumosudil) tablets approved to treat adult and pediatric patients 12 years and older with chronic graft-versus-host disease after failure of at least two prior lines of therapy

June 4, 2021

LUMAKRASTM (Sotorasib) Now Approved

LUMAKRAS (Sotorasib) Now Approved for the Treatment of Adult Patients with KRAS G12C-mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer

June 1, 2021

ALUNBRIG® Available From Onco360

ALUNBRIG® (brigatinib) Approved for the Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)-positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

March 15, 2021

Onco360 Selected as Partner for FOTIVDA

Onco360® Selected as Specialty Pharmacy Partner for FOTIVDA® (tivozanib)

December 17, 2020

Help Us Support Feeding America

Onco360® to provide 50,000 meals to children and families through Feeding America's network of food banks.

June 22, 2020

Second indication for Tazverik™

TAZVERIK™ (tazemetostat) is now approved for the treatment of relapsed/refractory follicular lymphoma, available from Onco360.

May 13, 2020

RETEVMO™ (selpercatinib)

Onco360® has been selected by Eli Lilly to be a specialty pharmacy partner for RETEVMO™ (selpercatinib), a novel oral treatment for adult patients with (RET) fusion-positive non-small cell lung cancer (NSCLC), RET-mutant medullary thyroid cancer (MTC) and metastatic RET fusion-positive thyroid cancer.

April 20, 2020

Tukysa™ (tucatinib)

Onco360®, has been selected by Seattle Genetics to be a specialty pharmacy partner for TUKYSA™ (tucatinib), a new oral treatment used in combination with capecitabine and trastuzumab for adult patients with HER2-positive metastatic breast cancer who have received one or more prior anti-HER2-based regimens in the metastatic setting.

April 13, 2020

Koselugo (selumetinib)

Onco360® has been selected by AstraZeneca to be a specialty pharmacy partner for KOSELUGO® (selumetinib), a novel oral kinase inhibitor indicated for the treatment of pediatric patients aged two years and above, with neurofibromatosis type 1 (NF1) who have symptomatic, inoperable plexiform neurofibromas.

March 13, 2020

Covid-19 Update For Patients

In response to the current COVID-19 situation, we’ve examined all areas of our business and pharmacy operations at every Onco360 location across the country and have taken actions to ensure continued service to our patients and their caregivers.

March 6, 2020

Onco360 Safety Awareness

Onco360 is aware of the emergence of the new coronavirus (COVID-19) illness and is closely monitoring the situation and possible future impact.

January 24, 2020

Tazverik™ (tazemetostat)

Onco360 has been selected by Epizyme to be the specialty pharmacy partner for TAZVERIK™ (tazemetostat), a new oral treatment for adult and pediatric patients (aged 16 years and older) with metastatic or locally advanced epithelioid sarcoma not eligible for complete resection.

January 15, 2020

Now Dipensing ENHERTU®

ENHERTU® now available from Onco360.

November 21, 2019

Now dispensing BRUKINSA™

BRUKINSA™ Now Available from Onco360

August 16, 2019

Now Dispensing INREBIC®

Onco360 is privileged to be selected as a specialty pharmacy provider for INREBIC®.

July 30, 2019

Dispensing NUBEQA®

NUBEQA® is available now through Onco360 Oncology Specialty Pharmacy.

July 11, 2019

Inclement Weather Alert

The impact of the budding hurricane, Tropical Storm Barry, on the Gulf of Mexico region is expected to be significant and may affect our pharmacy operations and delivery in limited areas.

July 3, 2019

Now Dispensing XPOVIO™

Onco360 is selected as 1 of 3 specialty pharmacies to dispense XPOVIO™ (selinexor).

June 5, 2019

Ron Bookman Scholarship Announced

The National Association of Specialty Pharmacy (NASP) has announced a scholarship program created in memory of our friend and colleague, Ron Bookman.

March 10, 2019

In Loving Memory

It is with great sadness that we announce the passing of our friend and colleague, Ron Bookman, on March 5, 2019.

November 30, 2018

Selected to Dispense XOSPATA

Onco360 was selected as 1 of only 3 Specialty Pharmacy providers to dispense XOSPATA® (Gilteritinib) for the treatment of patients with relapsed or refractory FMS-like Tyrosine Kinase 3 (FLT3) mutation-positive acute myeloid leukemia (AML).

November 1, 2018

Dispensing Talzenna + Vizimpro

Talzenna® and Vizimpro® available now through Onco360 Oncology Specialty Pharmacy.

October 3, 2018

Exclusive Provider for Libtayo

Onco360 Selected as the Exclusive Specialty Pharmacy for Libtayo® (cemiplimab-rwlc) Limited Distribution Pharmacy Network.

July 2, 2018

Braftovi + Mektovi Available Now

Onco360 selected to participate in the limited distribution network for Array Biopharma’s new products BRAFTOVI™ (encorafenib) and MEKTOVI® (binimetinib) for the treatment of patients with unresectable or metastatic melanoma with a BRAFV600E or BRAFV600K mutation, as detected by an FDA-approved test.

March 22, 2018

Imbruvica New Formulation

Now Available From Onco360 - The New IMBRUVICA® pill is now available as a one pill, once a day treatment.

October 16, 2017

Selected for VERZENIO LD Network

Onco360 has been selected to participate in the limited distribution network for Eli Lilly's new product, VERZENIO (Abemaciclib)

August 1, 2017

NERLYNX Available From Onco360

Onco360 announces selection to highly limited pharmacy network for NERLYNX.

April 14, 2016

Venclexta Available From Onco360

Onco360 announces selection to highly limited pharmacy network for VENCLEXTA.

March 22, 2016

New Indication for Xalkori

Limited distribution medication XALKORI (crizotinib) receives approval for certain NSCLC patients.

March 7, 2016

Second Indication for Ibrance

Limited distribution breast cancer medication IBRANCE approved for additional indication.

February 9, 2016

Generic Imatinib Now Available

Imatinib Mesylate (generic Gleevec) was recently approved for 7 indications.

January 25, 2016

OPDIVO+YERVOY Combo Receives New Indication

Combination therapy receives accelerated approval for new indication. OPDIVO also receives additional indication as a single therapy.

October 7, 2015

Onco360 Picked for Lonsurf

Onco360 Selected for Lonsurf Limited Distribution Pharmacy Network

June 16, 2015

Onco360 Achieves URAC Accreditation

Onco360 Receives URAC Specialty Pharmacy Accreditation...

February 9, 2015

Ibrance® (palbociclib) Available Through Onco360

Newly Approved Ibrance® (palbociclib) From Pfizer Available Through Onco360; Company Again Selected as Limited Distribution Pharmacy Provider

January 5, 2015

Bayer Selects Onco360 for LDD Network

Onco360 Chosen By Bayer As Limited Distribution Pharmacy Provider
Company’s Comprehensive Drug Portfolio Further Expands with Addition of Two Leading Products

December 1, 2014

Onco360 Adds 4 Pfizer LDD Products

Onco360 Selected by Pfizer as Limited Distribution Pharmacy Provider;
Expands Onco360’s Industry-Leading Portfolio to Nearly 40 Products

October 27, 2014

Onco360 Appoints New President & CEO

Onco360 Appoints Paul Jardina as President and Chief Executive Officer
Jardina Brings More Than 20 Years of Healthcare Industry Experience

July 23, 2014

Zydelig Available From Onco360

Zydelig® (idelalisib) approved and available for order through Onco360